Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia

Schizophrenia Research

Volumn 59, Issue 1, 2003, Pages 67-71

  Chong, S A ^a   Mythily, ^a   Remington, G ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Akathisia; Antipsychotics; Dyskinesia; Movement disorders; Schizophrenia

Indexed keywords

ATENOLOL; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; NEUROLEPTIC AGENT; TRIHEXYPHENIDYL;

ADULT; AKATHISIA; ARTICLE; ASIA; CONTROLLED STUDY; DISEASE PREDISPOSITION; DYSKINESIA; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SCHIZOPHRENIA; SINGAPORE; SOCIOECONOMIC FACTORS;

EID: 0037210033     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00156-1     Document Type: Article

References (27)

1. American Psychiatric Association Practice Guidelines for the Treatment of Patients with Schizophrenia. 1997;American Psychiatric Press, Washington, DC.
2. Ayd F.J. A survey of drug-induced extrapyramidal reactions. JAMA, J. Am. Med. Assoc. 175:1961;1054-1060.
3. Barnes T.R. A rating scale for rating drug-induced akathisia. Br. J. Psychiatry. 154:1989;672-676.
4. Barnes T.R., Braude W.M. Persistent akathisia associated with early tardive dyskinesia. Postgrad. Med. J. 60:1984;359-361.
5. Barnes T.R., Braude W.M. Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry. 42:1985;874-878.
6. Braude W., Barnes T.R., Gore S.M. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric in patient admissions. Br. J. Psychiatry. 143:1983;139-150.
7. Chong S.A., Sachdev P., Mahendran R., Chua H.C. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in the state psychiatric hospital in Singapore. Aust. N. Z. J. Psychiatry. 34:2000;988-991.
8. Curry S.H. The strategy and value of neuroleptic drug monitoring. Commentary J. Clin. Psychopharmacol. 5:1985;263-271.
9. Drake R.E., Ehrlich J. Suicide attempts associated with akathisia. Am. J. Psychiatry. 142:1985;499-501.
10. Eichhammer P., Albus M., Borrmann-Hassenbach M., Schoeler A., Putzhammer A., Frick U.et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am. J. Med. Gen. (Neuropsychiatric Genetics). 96:2000;187-191.
11. Gold R., Lennox R.H. Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. J. Clin. Psychiatry. 56:1995;476-483.
12. Goswami U., Channabasavana S.M. Is akathisia a forerunner of tardive dyskinesia? A clinical report with brief review of the literature. Clin. Neurol. Neurosurg. 86:1984;107-110.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. 1976;534-537 US Dept. of Health, Education and Welfare, Washington, DC.
14. Halstead S.M., Barnes T.R., Speller J.C. Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br. J. Psychiatry. 164:1994;177-183.
15. Inada T., Yagi G., Kaijima K., Ohnishi K., Kamasada M., Rockhold R.W. Clinical variants of tardive dyskinesia in Japan. Jpn. J. Psychiatry Neurol. 45:1991;67-71.
16. Kane J.M., Aguglia A.E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W.et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur. Neuropsychopharmacol. 8:1998;55-66.
17. Sachdev P. The neuropsychiatry of brain iron. J. Neuropsychiatry Clin. Neurosci. 5:1993;18-29.
18. Sachdev P. Treatment of Drug-induced Akathisia in Akathisia and Restless Legs. 1995;Cambridge Univ. Press, New York.
19. Sachdev P. The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr. Bull. 21:1995;431-449.
20. Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisia. Schizophr. Bull. 21:1995;451-461.
21. Sachdev P., Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch. Gen. Psychiatry. 51:1994;963-974.
22. Sachdev P., Loneragan C. The present status of akathisia. J. Nerv. Ment. Dis. 179:1991;381-391.
23. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia (letter). Arch. Gen. Psychiatry. 39:1982;486-487.
24. Segman R., Neeman U., Heresco-Levy U.et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry. 4:1999;247-253.
25. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212(S):1970;11-19.
26. Steen V.M., Lovlie R., Macewan T., McCreadie R.G. Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry. 2:1997;139-145.
27. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch. Gen. Psychiatry. 31:1974;67-72.